echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Diabetes Care: The new "star drug" dapagliflozin can effectively prevent and treat diabetic kidney disease

    Diabetes Care: The new "star drug" dapagliflozin can effectively prevent and treat diabetic kidney disease

    • Last Update: 2021-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Proteinuria is often a component of diabetic nephropathy
    .


    In observational studies and clinical trials, regardless of whether people with diabetes, the presence of albuminuria are associated with adverse renal and cardiac vascular risk (CV) outcomes associated with increased, while reducing the incidence of proteinuria and renal adverse CV outcomes Decrease related


    Proteinuria is often a component of diabetic nephropathy


    Sodium-glucose cotransporter 2 inhibitors (SGLT2i) can reduce the risk of adverse renal outcomes in patients with type 2 diabetes, including reducing the deterioration of estimated glomerular filtration rate (eGFR) and progression to end-stage renal disease (ESKD)


    The effect of dapagliflozin on cardiovascular events (DECLARE-TIMI 58) is a trial for 17,160 patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) (59.
    4%) or established ASCVD (eASCVD).
    ) (40.
    6%) of CVOT, which proved that one of the two main curative effects of CV death and heart failure hospitalization was significantly reduced by 17%
    .

    Cardiovascular events proved that one of the two main curative effects of CV death and heart failure hospitalization was significantly reduced by 17%
    .


    It proved that one of the two main curative effects of CV death and heart failure hospitalization was significantly reduced by 17%


    DECLARE-TIMI 58 randomly assigned 17160 patients with type 2 diabetes, creatinine clearance rate >60 ml/min, and atherosclerotic cardiovascular disease (CVD; 40.
    6%) or CVD risk factors (59.
    4%) to reach Gligliflozin Or the placebo group
    .


    Urine protein-creatinine ratio (UACR) was tested at baseline, 6 months, 12 months, and every year thereafter


    Results A total of 16643 (98.
    15%) participants were included in the baseline UACR: 9067 (53.
    83%) ≤15 mg/g, 2,577 (15.
    30%) >15 to <30 mg/g, 4,030 (23.
    93%) 30-300 mg/g, and 1,169 (6.
    94%) >300 mg/g
    .


    As a continuous variable, compared with placebo, the use of dapagliflozin improved from baseline to 4.


    Compared with placebo, the use of dapagliflozin improved from baseline to 4.


    Changes in UACR of each treatment group at baseline UACR, 6 months, 1 year, 2 years, 3 years, and 4 years

    Among them, dapagliflozin compared with placebo, UACR continued to confirm ≥1 category improvement is more common (OR=1.
    45[95% CI 1.
    35-1.
    56], P<0.
    0001)
    .


    In the subgroup with UACR≥30 mg/g, the use of dapagliflozin can reduce the heart and kidney outcomes (P<0.


    In the subgroup with UACR≥30 mg/g, the use of dapagliflozin can reduce the heart and kidney outcomes (P<0.


    In DECLARE-TIMI 58, dapagliflozin showed beneficial effects on various baseline UACR and kidney-specific results, including patients with normal protein excretion


    references:

    The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.


    The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.